Aurobindo gets FDA's OK for generic Salagen
Aurobindo has received the Food and Drug Administration’s clearance for pilocarpine hydrochloride tablets in 5 mg and 7.5 mg dosage strengths.
Aurobindo's product is the generic of Eisai’s Salagen.
Pilocarpine hydrochloride tablets are indicated for the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and the treatment of symptoms of dry mouth in patients with Sjogren’s Syndrome.
Pilocarpine hydrochloride tablets had a market value of $18 million for the 12 months ending June 2019, according to IQVIA.
Aurobindo's product is the generic of Eisai’s Salagen.
Pilocarpine hydrochloride tablets are indicated for the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and the treatment of symptoms of dry mouth in patients with Sjogren’s Syndrome.
Pilocarpine hydrochloride tablets had a market value of $18 million for the 12 months ending June 2019, according to IQVIA.